Eir Partners has made a strategic growth investment and taken a controlling interest in QuartzBio, a life science technology company providing AI-enabled sample and biomarker intelligence for clinical-stage biopharma, enabling platform scalability, deeper AI automation, and expanded interoperability.
QuartzBio, a life science technology company delivering portfolio-scale sample and biomarker intelligence for clinical-stage biopharma, has announced a strategic growth investment and controlling interest from Eir Partners, a private equity firm focused on health tech and tech-enabled services, according to official disclosures.
QuartzBio’s vendor-agnostic, AI-enabled platform unifies sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem. The company reports that customers gain near-complete visibility into sample collection, reducing monitoring effort by up to 98% and delivering average savings of $250,000–$350,000 per Phase II/III study.
This development matters because clinical trial sponsors currently manage biospecimens and biomarker data across disconnected vendors, systems, and spreadsheets, creating operational blind spots that lead to missing samples, data gaps, rework, and trial delays. QuartzBio is trusted by multiple top 10 pharmaceutical companies.
The Eir investment will accelerate platform enhancements including expanded portfolio-scale interoperability across CROs, labs, and clinical systems; deeper AI-driven automation for workflow management and risk detection; enhanced analytics; and increased enterprise scalability, security, and global compliance. Industries impacted include clinical trial management, biomarker analytics, and health technology.
Stakeholders include biopharma R&D teams, contract research organizations (CROs), and clinical laboratories.
For investors, the controlling stake signals private equity confidence in tech-enabled solutions addressing operational bottlenecks in drug development. Success will depend on continued adoption by large pharma and seamless integration with existing clinical workflows.
QuartzBio is a life science technology company providing sample and biomarker intelligence software for biopharma.
Eir Partners is a private equity firm focused on health tech and tech-enabled services headquartered in the United States.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.